Intersect ENT (NASDAQ:XENT)‘s stock had its “buy” rating restated by equities researchers at Guggenheim in a research report issued to clients and investors on Friday. They presently have a $41.00 price objective on the medical equipment provider’s stock. Guggenheim’s price objective would suggest a potential upside of 28.73% from the company’s current price.

XENT has been the topic of several other research reports. Bank of America lifted their price objective on Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Zacks Investment Research lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Canaccord Genuity lifted their price objective on Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Wednesday, September 13th. Piper Jaffray Companies reissued a “buy” rating and set a $35.00 price objective on shares of Intersect ENT in a report on Tuesday, August 22nd. Finally, BidaskClub lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $33.38.

Intersect ENT (NASDAQ:XENT) opened at $31.85 on Friday. Intersect ENT has a 1 year low of $11.00 and a 1 year high of $34.40.

Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The company had revenue of $22.31 million for the quarter, compared to analyst estimates of $21.53 million. During the same quarter last year, the firm earned ($0.22) EPS. Intersect ENT’s revenue for the quarter was up 20.8% compared to the same quarter last year. sell-side analysts predict that Intersect ENT will post -0.63 EPS for the current fiscal year.

In other Intersect ENT news, General Counsel David Aaron Lehman sold 36,000 shares of the business’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $32.75, for a total value of $1,179,000.00. Following the transaction, the general counsel now owns 45,000 shares of the company’s stock, valued at $1,473,750. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $27.78, for a total value of $356,500.74. Following the completion of the transaction, the chief financial officer now directly owns 27,833 shares in the company, valued at approximately $773,200.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 129,838 shares of company stock worth $3,892,610. 13.70% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can acquired a new position in Intersect ENT in the third quarter worth $116,000. Oppenheimer Asset Management Inc. acquired a new position in Intersect ENT in the third quarter worth $117,000. Legal & General Group Plc boosted its stake in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 255 shares in the last quarter. Moors & Cabot Inc. acquired a new position in Intersect ENT in the second quarter worth $205,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Intersect ENT in the third quarter worth $228,000. 86.31% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/15/intersect-ent-xent-given-buy-rating-at-guggenheim.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.